Asma Dilawari

870 total citations
29 papers, 256 citations indexed

About

Asma Dilawari is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Asma Dilawari has authored 29 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Asma Dilawari's work include Breast Cancer Treatment Studies (8 papers), Advanced Breast Cancer Therapies (5 papers) and BRCA gene mutations in cancer (4 papers). Asma Dilawari is often cited by papers focused on Breast Cancer Treatment Studies (8 papers), Advanced Breast Cancer Therapies (5 papers) and BRCA gene mutations in cancer (4 papers). Asma Dilawari collaborates with scholars based in United States, China and France. Asma Dilawari's co-authors include Christopher Gallagher, Zev M. Nakamura, Jaeil Ahn, Andrew J. Saykin, Richard Pazdur, Brenna C. McDonald, Jeanne S. Mandelblatt, Wanting Zhai, Kathleen Van Dyk and Judith Carroll and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Asma Dilawari

26 papers receiving 250 citations

Peers

Countries citing papers authored by Asma Dilawari

Since Specialization

Citations

This map shows the geographic impact of Asma Dilawari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Asma Dilawari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Asma Dilawari more than expected).

Fields of papers citing papers by Asma Dilawari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Asma Dilawari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Asma Dilawari. The network helps show where Asma Dilawari may publish in the future.

Co-authorship network of co-authors of Asma Dilawari

This figure shows the co-authorship network connecting the top 25 collaborators of Asma Dilawari. A scholar is included among the top collaborators of Asma Dilawari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Asma Dilawari. Asma Dilawari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor–Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2–Low or Human Epidermal Growth Factor Receptor 2–Ultralow Breast Cancer	Journal of Clinical Oncology	Asma Dilawari, Hui Zhang et al.	2
2	U.S. FDA analysis of enrollment of Asian patients from India in cancer clinical trials leading to approval from 2010 to 2022.	Journal of Clinical Oncology	Geetika Srivastava, Rupert W. Leong et al.	1
3	US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations	Journal of Clinical Oncology	Asma Dilawari, Christy Osgood et al.	13
4	Underrepresentation of Asian Americans, Native Hawaiians, and other Pacific Islanders (AA & NHPI) in cancer clinical trials that led to FDA approvals in 2010-2022.	Journal of Clinical Oncology	Rupert W. Leong, Jennifer J. Lee et al.	1
5	US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer	Journal of Clinical Oncology	Preeti Narayan, Asma Dilawari et al.	34
6	HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane	Breast Cancer Research and Treatment	Paula R. Pohlmann, Deena Graham et al.	4
7	Associating persistent self-reported cognitive decline with neurocognitive decline in older breast cancer survivors using machine learning: The Thinking and Living with Cancer study	Journal of Geriatric Oncology	Kathleen Van Dyk, Jaeil Ahn et al.	5
8	Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development	Cancer Discovery	Elizabeth S. Duke, Michael Fusco et al.	6
9	Loneliness and mental health during the COVID‐19 pandemic in older breast cancer survivors and noncancer controls	Cancer	Kelly E. Rentscher, Xingtao Zhou et al.	55
10	Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer	Cancer	Filipa Lynce, Matthew Blackburn et al.	14
11	Abstract P2-10-10: Lower pathologic complete response rate with dual-HER2 blockage and chemotherapy in African Americans and ethnic minorities	Cancer Research	Shruti Tiwari, Prasun Mishra et al.	1
12	Innovation, education, and research: A multidisciplinary survivorship care model.	Journal of Clinical Oncology	James E. Shaw, Eric Wisotzky et al.	0
13	PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer	Contemporary Clinical Trials Communications	Filipa Lynce, Ayesha N. Shajahan‐Haq et al.	8
14	Providers’ perspectives on adherence to hormonal therapy in breast cancer survivors. Is there a role for the digital health feedback system?	Health and Technology	Asma Dilawari, Jeanine Warisse Turner et al.	11
15	Correlates of Triple Negative Breast Cancer and Chemotherapy Patterns in Black and White Women With Breast Cancer	Clinical Breast Cancer	Vanessa B. Sheppard, Luciane R. Cavalli et al.	9
16	Video intervention increases participation of black breast cancer patients in therapeutic trials	npj Breast Cancer	Eshetu Tefera, Pia Herbolsheimer et al.	20
17	Lung cancer trends: smoking, obesity, and sex assessed in the Staten Island University’s lung cancer patients	International Journal of General Medicine	Houssein Abdul Sater, Shilpi Gupta et al.	6
18	Patterns of 21-Gene Assay Testing and Chemotherapy Use in Black and White Breast Cancer Patients	Clinical Breast Cancer	Vanessa B. Sheppard, Suzanne C. O’Neill et al.	8
19	Intracranial Rosai-Dorfman	The Neurologist	Rabih Said, Asma Dilawari et al.	11
20	Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers	ecancermedicalscience	Asma Dilawari	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact